Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs

Expert Review of Gastroenterology & Hepatology
Kristian ThorlundEdward J Mills

Abstract

To conduct a network meta-analysis (NMA) to establish the comparative efficacy of infliximab, adalimumab and golimumab for the treatment of moderately to severely active ulcerative colitis (UC). A systematic literature search identified five randomized controlled trials for inclusion in the NMA. One trial assessed golimumab, two assessed infliximab and two assessed adalimumab. Outcomes included clinical response, clinical remission, mucosal healing, sustained clinical response and sustained clinical remission. Innovative methods were used to allow inclusion of the golimumab trial data given the alternative design of this trial (i.e., two-stage re-randomization). After induction, no statistically significant differences were found between golimumab and adalimumab or between golimumab and infliximab. Infliximab was statistically superior to adalimumab after induction for all outcomes and treatment ranking suggested infliximab as the superior treatment for induction. Golimumab and infliximab were associated with similar efficacy for achieving maintained clinical remission and sustained clinical remission, whereas adalimumab was not significantly better than placebo for sustained clinical remission. Golimumab and infliximab were al...Continue Reading

References

Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Feb 28, 2007·The American Journal of Gastroenterology·Brian G FeaganStephen B Hanauer
Mar 31, 2012·International Journal of Epidemiology·Rebecca M TurnerJulian Pt Higgins
Jun 6, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-SC Study Group
Jun 19, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-Maintenance Study Group

❮ Previous
Next ❯

Citations

Dec 19, 2015·Expert Review of Clinical Pharmacology·A S StrikM Löwenberg
Jan 26, 2016·Pharmacology & Therapeutics·Caroline Meyer OlesenOle Haagen Nielsen
Mar 5, 2016·Inflammatory Bowel Diseases·Ashwin N AnanthakrishnanShawn N Murphy
Aug 9, 2016·Expert Review of Clinical Pharmacology·Saurabh KediaGovind K Makharia
Dec 7, 2016·Expert Opinion on Drug Safety·Nikola Mitrev, Rupert W Leong
Mar 10, 2017·Expert Review of Gastroenterology & Hepatology·Anne S StrikMark Löwenberg
May 5, 2017·Expert Opinion on Biological Therapy·Mathurin FlamantXavier Roblin
May 10, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Mark T Osterman, Gary R Lichtenstein
Jan 3, 2018·Journal of Crohn's & Colitis·Tomer GreenerMark S Silverberg
Jun 18, 2017·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Chris CameronMichael Ingham
Jul 27, 2018·Frontline Gastroenterology·Jimmy K Limdi
Feb 8, 2019·Current Medical Research and Opinion·Abhishek VaruChris Cameron
Dec 14, 2016·Journal of Gastroenterology and Hepatology·Yuga KomakiAtsushi Sakuraba
Sep 1, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Karen SmithGraciela Gonzalez-Hernandez
May 13, 2018·Clinical Pharmacokinetics·Sophie E BerendsRon A A Mathôt
May 9, 2019·Revista da Associação Médica Brasileira·Fabio Vieira TeixeiraSender Jankiel Miszputen
Sep 13, 2018·Clinical Journal of Gastroenterology·Gabriele DragoniFrancesca Rogai

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.